Recent analyst reports have consistently maintained buy recommendations on OS Therapies, reflecting positive market interest. The company is progressing regulatory submissions for OST-HER2 in multiple jurisdictions and advancing clinical and biomarker data disclosures.

• D. Boral Capital maintained a buy recommendation on OS Therapies in multiple reports from September 2025 through December 2025 [N1][N2][N3][N4][N6][N7][N8].
• Lake Street also maintained a buy recommendation in November 2025 [N5].
• OS Therapies has submitted Non-Clinical and CMC modules of its Biologics License Application to the FDA and plans clinical BLA submission and conditional Marketing Authorization Applications to MHRA and EMA in Q2 2026 [S1].
• The company announced positive immune biomarker data correlating with overall survival in January 2026 [S1].

OS Therapies has demonstrated statistically significant clinical trial results for OST-HER2 in Osteosarcoma, including improved event-free and overall survival compared to historical controls, which supports regulatory submissions in the US, UK, and EU. The orphan drug and rare pediatric disease designations may provide market exclusivity and potential priority review benefits. The company’s OST-tADC platform offers a novel approach to targeted drug delivery with tunable linkers and conditionally active payloads, potentially expanding its therapeutic reach beyond Osteosarcoma to other solid tumors. Multiple recent analyst buy recommendations reflect positive market sentiment and confidence in the company’s clinical progress and pipeline potential.

OS Therapies faces significant financial challenges, including limited cash resources, a current ratio of 0.18, and recurring operating losses, raising substantial doubt about its ability to continue as a going concern. The company’s secured notes impose operational restrictions and risk asset foreclosure upon default. The Phase IIb clinical trial was open-label and compared to historical controls rather than a randomized control arm, which may limit regulatory acceptance. Additional clinical data, including randomized trials, may be required by regulators, potentially delaying approval. The OST-tADC platform remains in preclinical development, and the company’s ability to commercialize products depends on successful regulatory approvals and financing.

OS Therapies' moat is primarily based on its proprietary OST-HER2 immunotherapy platform targeting a rare and underserved indication, Osteosarcoma, with orphan drug and rare pediatric disease designations providing potential market exclusivity. The company has generated clinical data demonstrating statistically significant survival benefits in a difficult-to-treat patient population, which supports regulatory engagement and potential approval pathways. Additionally, the OST-tADC platform represents a novel tunable antibody-drug conjugate technology with pH-sensitive linkers and conditionally active payloads, which may offer differentiated therapeutic options in solid tumors. The company's acquisition of related immune-oncology assets and intellectual property from Ayala Pharmaceuticals further strengthens its pipeline. However, the clinical programs remain in early to mid-stage development, and regulatory approvals are pending. The company's financial constraints and reliance on external financing may impact its ability to fully capitalize on its technological advantages.

• Financial and Liquidity Risk: The company has limited cash resources, a low current ratio of 0.18 as of June 30, 2026, and recurring losses, raising substantial doubt about its ability to continue as a going concern. Secured Notes mature within nine months and impose operational restrictions, with risk of asset foreclosure upon default [S2].
• Regulatory Approval Risk: OST-HER2’s Phase IIb trial was open-label and compared to historical controls, which may not satisfy regulatory requirements. The FDA may require additional randomized clinical trials before approval, potentially delaying or preventing market entry [S1].
• Clinical Development Risk: The clinical data, while statistically significant, are based on a relatively small patient population and exploratory biomarker analyses that have not been validated as surrogate endpoints. The OST-tADC platform is in preclinical stages, with uncertain development timelines and outcomes [S1].
• Market and Commercialization Risk: The company’s ability to commercialize OST-HER2 and other products depends on successful regulatory approvals, manufacturing scale-up, and market acceptance. The veterinary indication strategy is uncertain, with prior conditional licenses allowed to lapse [S1].
• Operational and Financing Restrictions: The Secured Notes contain covenants restricting dividends, asset sales, indebtedness, and other activities, which may limit operational flexibility and strategic options [S2].

• OS Therapies Inc is a clinical-stage biopharmaceutical company focused on treatments for Osteosarcoma and other solid tumors, targeting cancers of the bone in children and young adults [S1].
• The lead product candidate is OST-HER2 (also known as OST31-164), a cancer immunotherapy designed to produce a cellular immune response against the HER2 cancer antigen [S1].
• OST-HER2 is a genetically engineered strain of Listeria monocytogenes expressing HER2 peptides, designed as an off-the-shelf immunotherapy [S1].
• OST-HER2 has orphan drug designation and rare pediatric disease designation from the FDA [S1].
• The company completed a Phase IIb clinical trial for OST-HER2 in recurrent pulmonary metastatic Osteosarcoma, fully enrolling 41 patients by October 2023 [S1].
• The Phase IIb trial met its primary endpoint with statistical significance, showing 33% event-free survival at 12 months compared to 20% historical control [S1].
• Final two-year overall survival data showed 75% survival in OST-HER2 treated patients versus 40% in historical controls (p < 0.0001) [S1].
• OST-HER2 was generally well tolerated with no Grade 5 treatment-emergent adverse events reported in the Phase IIb trial [S1].
• Exploratory biomarker analyses showed activation of interferon gamma pathway markers correlated with overall survival, distinguishing long-term survivors [S1].
• The company is engaging with FDA, MHRA, and EMA regarding regulatory pathways and submitted Non-Clinical and CMC modules of a Biologics License Application (BLA) to FDA in January 2026 [S1].
• OST-HER2 regulatory submissions to MHRA and EMA are planned for Q2 2026, with confirmatory clinical studies anticipated in Q3 2026 [S1].
• The company owns rights to OST-tADC, a tunable antibody-drug conjugate platform in preclinical development targeting solid tumors [S1].
• OST-tADC uses pH-sensitive silicone linkers (SiLinkers™) and conditionally active payloads (CAPs™) designed for targeted delivery and release in tumor microenvironments [S1].
• The company acquired HER2 and Listeria monocytogenes-based immune-oncology programs and related IP assets from Ayala Pharmaceuticals in 2025, including INDs for lung and prostate cancer [S1].
• OST-HER2 is also being developed for veterinary use in canine Osteosarcoma, with a prior conditional USDA license that lapsed; future veterinary strategies are under evaluation [S1].
• The company had cash and equivalents of approximately $205,000 and an accumulated deficit of about $86.2 million as of June 30, 2026 [S2].
• Current assets were $3.64 million and current liabilities $20.64 million as of June 30, 2026, resulting in a current ratio of 0.18 and cash ratio of 0, indicating liquidity constraints [S2].
• The company issued Secured Notes totaling $5.4 million in August 2026, secured by a first-priority lien on most assets except intellectual property, with maturity nine months from advance date [S2].
• The Secured Notes impose operational and financing restrictions and contain events of default that could accelerate obligations and lead to loss of assets [S2].
• The company has recurring losses and negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern [S2].
• Multiple recent analyst reports from D. Boral Capital and Lake Street maintain buy recommendations on OS Therapies, reflecting positive market interest [N1][N2][N3][N4][N5][N6][N7][N8].